Introduction
Mutations in the gene for lamin A and lamin C (LMNA) are associated with the development of cardiac conduction disease (CCD), atrial and ventricular arrhythmias (VA), muscular dystrophy, and dilated cardiomyopathy (DCM).
1,2 A European multicentre study of 269 LMNA mutation carriers suggested that the presence of two or more risk factors, including an episode of non-sustained ventricular tachycardia (VT), a left ventricular ejection fraction (LVEF) <45%, male sex, and non-missense mutations, was associated with a high risk of malignant VA and sudden cardiac death (SCD). 3, 4 These observations were recently confirmed in a study of 122 LMNA mutation carriers in the US. 5 However, novel data suggest that some LMNA mutations may be associated with a more benign outcome. 6 Lamin A and lamin C proteins constitute the main structural proteins of the inner nuclear envelope. Both isoforms are encoded by the LMNA gene, and are formed after alternative splicing. 7 They are expressed in almost all differentiated tissues, including the myocardium and fibroblasts. In addition to their structural and supportive function of the nucleus, these proteins are believed to influence regulation of gene expression through an interaction with transcription factors, DNA, and chromatin. 7 It has been suggested that haploinsufficiency is the disease mechanism in patients carrying truncating LMNA mutations, while LMNA missense mutations have been proposed to act through a dominant negative pathway. 8 -10 A recent study of a missense mutation suggested that mutant lamin protein may accumulate and form intra-nuclear aggregates and thereby exhibit a dominant negative effect.
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In the current study, we report the disease expression associated with a LMNA-p.Arg216Cys variant in a large family with 36 mutation carriers. The phenotype was remarkable since most of the affected mutation carriers had a late onset of disease manifestations and a favourable prognosis. Furthermore, we describe two additional LMNA families with a total of 17 mutation carriers, which were characterized by an early onset and a severe disease expression of DCM. To elucidate if the highly variable disease expression observed in the three families was associated with different molecular disease mechanisms, we performed gene and protein expression studies in fibroblasts obtained from LMNA mutation carriers.
Methods

Subjects and clinical investigations
The study included three unrelated index patients who carried a disease-associated LMNA mutation and their relatives who accepted an offer of clinical investigation including 12-lead ECG recording, two-dimensional Doppler echocardiography, and 48 h Holter monitoring. DCM in index patients was defined as left ventricular end-diastolic volumes or diameters >2 standard deviations (SD) from normal and LVEF <45%. 12 VA were defined as sustained VT lasting >30 s, non-sustained VT as ≥3 ventricular ectopics with a frequency of >120 b.p.m., or as ventricular fibrillation. Relatives were diagnosed in accordance with recent recommendations. 13 The study was carried out in accordance with the principles of the Declaration of Helsinki. The local ethics committee approved the study and informed consent was obtained from all participants (protocol no. VEK S-20140073).
Genetic diagnosis
Index patients underwent genetic testing in 84 cardiac-related genes as previously reported, and relatives at risk were offered predictive testing for the specific variant identified in the index patient. 14 Genetic investigations of deceased individuals were made with DNA extracted from formalin-fixed paraffin embedded tissue.
Cell cultures
Fibroblast cell lines were cultured from skin biopsies of eight LMNA mutation carriers with following IDs as previously described: p.Arg216Cys: IV-6, IV-9, IV-10, V-9; p.Arg471His: III-3, III-5, IV-5; p.Arg471Cys: II-2. 9 Control fibroblast cell lines were obtained from Coriell Institute (GM08400, 42-year-old female donor; GM00321, 37-year-old female donor) and two from an anonymized in-house biobank (PKP236, 17-year-old female donor; PKP293, 17-year-old female donor) and were tested negative for LMNA variants by Sanger sequencing as previously described. 9 Quantitative reverse transcriptase polymerase chain reaction cDNA was synthesized from RNA extracted from cultured fibroblasts as previously described. 9 For quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis, custom designed Taqman gene expression assays covering both LMNA (Hs00153462_m1) and TUBA4A (Hs01081795_g1) transcripts were used.
Step One Plus (Life technologies) was used to analyse the samples as triple determinations. LMNA gene expression levels were normalized to -tubulin levels.
Western blotting
The cytoskeletal protein fractions were extracted from patient and control fibroblasts visualized by Western blotting (WB) as previously described. 9 Primary antibodies used were: anti-lamin A/C (N-terminal epitope, Sigma-Aldrich, #HPA006660) and anti--tubulin (Sigma-Aldrich, #T6074), followed by incubation with secondary antibodies (goat-anti-mouse or goat-anti-rabbit-HRP, DAKO) in 1 h. ECL-Plus (Thermo Scientific) was used for protein detection. ImageQuant LAS 4000 (GE Healthcare) was used for visualization.
Targeted mass spectrometry analysis of lamin proteins
Targeted mass spectrometry analysis of lamin proteins was performed using a previously described and thoroughly validated protocol with heavy labelled peptides as internal standards. 15 For quantitation of lamin A/C peptides, 25 g of the extracted proteins from the isolated cytoskeletal fraction from each sample was separated by SDS-PAGE. The gel pieces containing the proteins of interest, lamin A and lamin C, migrating between 100 and 40 kDa in-gel were digested by trypsin.
A mix of heavy labelled peptides covering the mutation sites and other parts of lamin A and lamin C (online supplementary Table S1 ) was added to each peptide sample, followed by selected reaction monitoring (SRM) using nano-liquid chromatography coupled with tandem mass spectrometry (TSQ Vantage, Thermo Scientific). 15 Skyline software was used to assure correct peptide identifications and to calculate the ratios between the light (endogenous) and the heavy (internal standard) peptides. 16 The peptide mass data were validated according to retention time and fragmentation pattern. For quantitation, the ratio of the area under the curve of endogenous peptide to heavy labelled peptide was calculated.
Histology and immunohistochemistry of cardiac tissue and fibroblasts
Formalin-fixed paraffin-embedded myocardial tissue was available from one carrier of each LMNA mutation (family A, ID IV-9, diagnostic myocardial biopsy from the right ventricle; family B, ID III-5, left ventricular biopsy from cardiac explant; family C, ID II-3, left ventricular biopsy obtained at autopsy) in addition to left ventricular samples from explanted hearts of four non-LMNA DCM patients. Four m thick formalin-fixed paraffin-embedded sections of myocardial tissue were plated on glass coverslips and were stained with either haematoxylin and eosin, or with mouse anti-lamin A/C antibody (#4C11, Cell Signalling technology) followed by incubation with anti-IgG mouse Alexa Fluor 488-conjugated antibody (Invitrogen). The slides were imaged using a confocal laser scanning microscope (Leica TCS SP8). Immunocytochemistry staining of cultured fibroblasts was performed with similar antibodies as previously described. 
Statistics
Continuous variables were considered normally distributed based on inspection of data histograms. Variables were expressed as means ±standard deviations. Variables expressing age were reported as means with ranges. Statistical analyses were performed with Prism version 5.0 software using a 2-tailed Student's t-test with a significance level of 0.05 if test assumptions of normality and variance homogeneity were not violated.
Results
Clinical investigations and genetic diagnosis Family A
The proband of family A (IV-9) presented at the age of 59 with sustained VT (Figure 1 and 2A, and online supplementary Table  S2 ). Following cardioversion, ECG monitoring showed sinus node dysfunction and advanced second degree atrioventricular block (AVB). Echocardiography showed a dilated left ventricle with a LVEF of 40%. An implantable cardioverter defibrillator (ICD) was implanted and he has subsequently received appropriate ICD therapy multiple times due to sustained VT. Genetic investigations identified a LMNA-p.Arg216Cys (NM_170707.3:c.646C > T) variant which was considered to be disease-associated since it segregated with the condition in the family, was absent in more than 60 000 ExAC exomes, and has been reported previously in one . 
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Clinical cascade screening identified 12 affected individuals (mean age 68 years, range: 59-87) who all carried the mutation ( Figure 1 and 2A, Table 1 and online supplementary Table S2 ). All had CCD with advanced AVB, of which six had been diagnosed before this investigation. Family investigations identified five patients with total AVB, of which one (III-8) declined the offer of pacemaker implantation 2 years before he died at the age of 89 years. All but one (IV-6) had chronic or paroxysmal supraventricular arrhythmia while eight fulfilled diagnostic criteria of familial DCM with an average LVEF of 40%. Only one relative (IV-4) received appropriate ICD therapy during follow-up, while another (IV-27) received a cardiac transplant at the age of 50 due to end-stage heart failure. This patient, however, had extensive cardiac sarcoidosis confirmed by histological examination of the explanted heart, which was believed to be the main cause of her condition.
A total of 17 healthy mutation carriers (mean age 49 years, range: 23-68; online supplementary Table S2 ) were identified. Five of these individuals developed advanced AVB with preserved left ventricular function and no significant VA during an average follow-up of 5.2 years at a mean age of 60 years (range: 55-69). One younger mutation carrier (V-9) had 10% monomorphic premature at an average age of 77 years, which indicated a near-normal life expectancy despite their genotype. In summary, during this investigation, 20 of 36 (46%) mutation carriers were affected or developed disease manifestations that required device implantation at an average age of 61.7 years. Although all affected individuals had or developed advanced AVB requiring pacemaker implantation, only two patients (5%) including the proband had significant VA. Only nine of 36 (25%) mutation carriers fulfilled the diagnostic criteria of DCM.
Family B
The proband (III-3) was diagnosed with DCM (LVEF 35%) at the age of 54 and has remained stable on heart failure therapy for the past 6 years ( Figure 1 and 2B, Table 1 and online supplementary  Table S2 ). Her son (IV-6) died suddenly at the age of 18 while at rest and autopsy revealed an enlarged heart consistent with a diagnosis of DCM. The brother (IV-5) of the deceased was diagnosed with DCM (LVEF 40%) at the age of 25 and was treated with a prophylactic ICD from which he has received appropriate anti-tachycardia pacing once during 12 years of follow-up. Family investigations identified three additional surviving relatives with DCM, of which one (III-5) received a cardiac transplant at the age of 59. Four mutation carriers had died prior to this investigation from chronic heart failure (CHF) at an average age of 61 years.
Genetic investigations identified a LMNA-p.Arg471His/c.1412G > A mutation. The mutation co-segregated with the disease in the family. Genetic cascade screening identified three healthy gene carriers with an average age of 38 years (one individual lost to follow-up). The p.Arg471His mutation was considered pathogenic since it co-segregated with the DCM phenotype in this family, was absent in the ExAC control exomes, 17 and has been reported previously in DCM patients.
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Family C
The proband was diagnosed at the age of 41 with atrial fibrillation (Figure 1 and 2C, Table 1 and online supplementary Table S2 ).
He later developed DCM with a LVEF of 45% and received a dual-chamber pacemaker at the age of 45 years due to total AVB. Four years later, he died suddenly at rest. Post-mortem examination of the heart was consistent with DCM. His sister developed DCM with an LVEF of 25% at the age of 38 years and has had episodes of non-sustained VT and sustained VT. Genetic investigations identified a LMNA-p.Arg471Cys/c.1411C > T missense mutation carried by both affected individuals. The same mutation has been identified in two additional unrelated probands with a cardiolaminopathy phenotype at our institutions (unpublished data) and in two patients with progeria syndrome who were homozygous and compound heterozygous mutation carriers, respectively. 21, 22 Therefore, p.Arg471Cys variant was considered to be a likely pathogenic variant since it was located in the same codon as the recognized disease-causing mutation identified in family B (p.Arg471His), and the frequency among ExAC control alleles was very low (3/117 104). 17 In summary, disease expression in family B and C appeared to be severe since 65% of mutation carriers had DCM, of which seven (47%) had died from either CHF or SCD. Surprisingly, no one had CCD as the primary disease manifestation. The average age of onset of disease was 48 years ( Table 1) .
LMNA gene and lamin A and C protein expression in mutant fibroblast cell lines
LMNA transcript and protein levels in fibroblast of mutation carriers were measured by qRT-PCR and WB and were not significantly different from control fibroblasts ( Figure 3A and 3B) . However, the specific expression of lamin C protein was significantly increased in mutation carriers ( Figure 3C ). This finding was supported by SRM mass spectrometry analysis, which showed that the expression of a lamin A-specific peptide relative to expression of common lamin A and lamin C peptides from p.Arg471His and p. patients was lower compared to peptides from control fibroblasts ( Figure 3D ). In accordance with the result by WB, this finding indicated that expression of the lamin C isoform was relatively increased compared to lamin A expression in mutation carriers.
Lamin A and C proteins in the cytoskeletal fraction of cells
Mutant lamin A/C peptides were identified and discriminated from wild-type (WT) peptides by use of heavy-isotope labelled mutant peptides in SRM mass spectrometry analysis. In p.Arg216Cys fibroblasts, SRM analysis was able to detect the endogenous mutant peptide NIYSEELCETK (red in Figure 4A , variation in bold) with high intensities ( Figure 4A) . Similarly, the mutant peptides HQNGDDPLLTYR and CQNGDDPLLTYR were detectable in p.Arg471His and p.Arg471Cys fibroblast cells, respectively ( Figure 4B and 4C) . As expected, the mutant peptides were not present in controls. Quantification of the WT peptide corresponding to the mutated p.Arg216Cys peptide demonstrated that the WT peptide accounted for approximately 70% of total lamin A and C protein in p.Arg216Cys fibroblasts ( Figure 4D ). In contrast, only 50% of the lamin protein was derived from the WT allele in the LMNA-p.Arg471His and LMNA-p.Arg471Cys carriers, indicating that these mutant lamin proteins were incorporated in the cytoskeletal fraction with similar efficiency as the WT protein ( Figure 4D ).
Immunohistology
Histological examination did not show any obvious differences between LMNA and non-LMNA DCM patients (online supplementary Figure S1 ). Antibody staining with an anti-LMNA antibody demonstrated nuclear staining in all LMNA patients without cytosolic aggregates, which indicated nuclear incorporation of mutant lamin protein. Additional immuno-staining of p.Arg471His fibroblasts showed a normal nuclear morphology without intracellular aggregates, supporting the expression and incorporation of mutated protein into the cytoskeleton (online supplementary Figure S2 ).
Discussion
Clinical and genetic investigations
Several clinical investigations have shown that LMNA mutations in cardiac conditions are associated with a severe prognosis and that the presence of specific risk factors is associated with an increased risk of VA and sudden death.
3 -5 Disease expression in family B and C was in accordance with previous findings and showed that more than half of the patients died from CHF or VA. In contrast, clinical investigations in family A, which included 36 carriers of the p.Arg261Cys mutation, showed a late onset of disease manifestations and a low frequency of VA. A substantial part of the mutation carriers had a near-normal life span of which one patient even survived until the age of 89 years without a pacemaker, -tubulin was used as a loading control. (C) Quantitation of band intensities, from Figure 3A , of lamin A (black bars) and lamin C (grey bars) relative to -tubulin. Columns represent the means of signal intensities of lamin A and lamin C relative to -tubulin. Error bars denote standard deviation; *P < 0.05. (D) Lamin A and lamin C ratio quantitation by selected reaction monitoring (SRM). Schematic overview of lamin A and lamin C (lamin A/C) common peptides 1-3 (black) and lamin A specific peptide 4 (grey) used for the quantitation of lamin A to lamin C ratio. The graphs represent relative quantitation of lamin A to lamin A/C peptides by SRM-nano-liquid chromatography-mass spectrometry (MS)/MS in control and patient fibroblasts. The quantitative robustness was improved by utilization of isotopically labelled peptide standards, for each quantified peptide, and by normalization to the reference protein -tubulin. Error bars denote standard deviation.
despite the presence of a complete AVB. Overall, disease expression was associated with an apparently mild phenotype and few adverse disease complications, which suggested that LMNA mutations may also be associated with a favourable prognosis. These findings were consistent with the results of a recent Dutch study . . . . . . . . . . . . . . . of a LMNA-p.Arg331Gln mutation in 57 mutation carriers, which was also associated with a low risk of VA, end-stage CHF and SCD. 6 So far, clinical and genetic data of LMNA families have largely been provided by investigations of highly selected families at tertiary referral centres, which may introduce selection bias towards more severely affected families. 1, 2, 4, 5, 23 The results of the current study underscore the importance of investigating the entire family and assess the phenotype of all individuals at risk of having inherited the condition to provide a firm basis for individualized risk assessment.
Expression studies
For the first time to our knowledge, protein mass spectrometry was used to perform targeted analyses of WT and mutant lamin A and C protein expression in heterozygous mutation carriers. The results showed that the mutated peptides were present in the cytoskeletal protein fraction and thereby likely to be incorporated into the nuclear lamin polymer. Furthermore, SRM revealed that the ratio of WT and mutated protein was 50:50 in fibroblasts obtained from mutation carriers of p.Arg471His and p.Arg471Cys in whom disease expression was associated with a severe outcome. Interestingly, the proportion of mutant protein was only 30% in mutation carriers of p.Arg216Cys, which may explain the apparently milder disease expression. These results indicated that the proportion of incorporated mutant lamin protein may serve as a prognostic marker of disease, which has the potential to improve current algorithms for risk assessment of individual LMNA families.
The mutations investigated were all located in the common region of lamin A/C and thereby expected to affect both isoforms equally. However, the experimental results indicated that protein expression levels of lamin A were unaffected in mutant cells. Surprisingly, the expression of lamin C protein was significantly increased in mutation carriers, leading to a decreased lamin A to lamin C ratio in LMNA carriers. This finding was also observed in our previous study of fibroblasts from carriers of a truncating LMNA-p.Arg321X mutation. 9 Similarly, a decreased lamin A to lamin C ratio at mRNA and protein level has been observed in patients with progeria and Emery-Dreifuss muscular dystrophy. 24, 25 The impact of these findings remains unclear and needs to be investigated further.
Immunohistochemistry of cardiac tissues and p.Arg471His fibroblasts did not show intracellular aggregates of mutant lamin protein (online supplementary Figures S1 and S2) . Therefore, it is likely that the combination of a skewed lamin A to C ratio and the incorporation of mutated protein may lead to destabilization of the nuclear envelope and impair the mechanical support of the nucleus. The results support the hypothesis that LMNA missense mutations act by a dominant negative disease mechanism. 20,26 -28 
Limitations
In the current study, skin fibroblasts were used as a surrogate tissue for cardiac myocytes since they were easy to obtain without risk of adverse complications compared to cardiac biopsies. The fibroblasts were obtained from human mutation carriers and thereby shared the same genetic background as cardiomyocytes. Thereby, potential bias was minimized compared to the use of in vitro expression studies of mutations introduced into cell systems unrelated to the patient. However, the current studies on protein functions in fibroblasts should ideally be confirmed 
Conclusion
The clinical investigations of a large family with a novel pathogenic LMNA mutation showed that the disease expression of LMNA mutations may also be associated with a favourable prognosis in contrast to the findings in the vast majority of previous reports. Furthermore, the results suggested that clinical outcome in LMNA mutation carriers may be associated with the amount of mutant peptide incorporated into the nuclear envelope.
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